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The Kaleidoscope of Microglial 
Phenotypes
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Gene expression analyses of microglia, the tissue-resident macrophages of the central 
nervous system (CNS), led to the identification of homeostatic as well as neurological 
disease-specific gene signatures of microglial phenotypes. Upon alterations in the neural 
microenvironment, either caused by local insults from within the CNS (during neurode-
generative diseases) or by macroenvironmental incidents, such as social stress, microglia 
can switch phenotypes—generally referred to as “microglial activation.” The interplay 
between the microenvironment and its influence on microglial phenotypes, regulated 
by (epi)genetic mechanisms, can be imagined as the different colorful crystal forma-
tions (microglial phenotypes) that change upon rotation (microenvironmental changes) 
of a kaleidoscope. In this review, we will discuss microglial phenotypes in relation to 
neurodevelopment, homeostasis, in vitro conditions, aging, and neurodegenerative dis-
eases based on transcriptome studies. By overlaying these disease-specific microglial 
signatures, recent publications have identified a specific set of genes that is differentially 
expressed in all investigated diseases, called a microglial core gene signature with multi-
ple diseases. We will conclude this review with a discussion about the complexity of this 
microglial core gene signature associated with multiple diseases.
Keywords: microglia, activation, phenotype, transcriptome, neurodegenerative diseases, core gene signature
iNTRODUCTiON
Macrophages are innate immune cells that reside in all organs of the body. They have versatile 
func tions that are tailored to the organ of residence (1). Genome-wide studies showed that 
microenvironment-specific signals establish tissue-specific properties of macrophages via epige-
netic mechanisms (2, 3).
Transcriptomic analyses are an effective way to determine gene expression patterns that serve 
as a proxy for different cellular states under different conditions. The last decade, numerous trans-
crip tome studies of (micro)glia have been published and provide much insight in glia biology (4, 5).
Gene expression profiling of purified microglia has confirmed that they are central nervous 
system (CNS)-resident macrophages that express many genes typical for the myeloid lineage, 
including receptors for pathogen-associated molecular patterns and damage-associated molecu-
lar patterns, genes involved in phagocytosis and antigen presentation. This makes distinction 
between microglia and macrophages, particularly under neuropathological circumstances, very 
difficult (6). A common approach to separate microglia from other cells of the periphery and 
CNS is the preparation of a single-cell suspension followed by fluorescence-activated cell sorting 
(FACS) based on the membrane expression of CD11bhigh and CD45low/int in mice and human (7). 
In mice, Ly6C/Ccr2 and Mrc1 are specifically expressed by monocytes (8) and CNS interface 
macrophages (9), respectively and can be additionally used to distinguish between these cells 
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and microglia. In humans, although not yet widely applied, 
CCR2 and CD14 are used to discriminate between microglia 
and monocytes (10).
In recent years, RNA expression profiling of microglia has 
received much attention (see the glia open access database) (11). 
This review will focus on microglial phenotypes in the CNS 
related to manifold processes associated with brain development, 
physiology, and pathology.
MiCROGLiA ORiGiN AND HOMeOSTASiS
Microglia Ontogeny
As already proposed by Río-Hortega in 1919 (12), sophisticated 
in vivo lineage tracing studies confirmed the mesodermal origin 
of microglia during embryogenesis (13–15). This is different from 
other CNS cells that arise from the neuro-ectoderm (16). Even 
within the mesoderm-originating myeloid cell compartment, 
microglia have a distinct ontogeny. In mice, tissue-resident 
macrophages emerge from two waves of erythromyeloid pro-
genitor (EMP) production (primitive and transient definitive 
hematopoiesis) in the extra-embryonic yolk sac (YS) prior to 
the establishment of definitive hematopoiesis in the fetal liver 
and later in adult bone marrow (14, 17). Microglia originate 
from the primitive hematopoietic wave of early EMP’s (primitive 
macrophages) at embryonic day 7.5 (E7.5) in the YS—a process 
dependent on the transcription factors (TFs) Spf1 (Pu.1) and 
Irf8 (14, 15).
These primitive macrophages spread via the bloodstream 
to the developing organs, including the neurepithelium, which 
gets colonized by primitive macrophages (microglia) as early 
as E9.5 (13). By contrast, other tissue-resident macrophages 
mainly develop from the transient definitive hematopoietic 
wave of late EMP’s arising at E8.5 in the YS. These late EMP’s 
subsequently colonize the fetal liver from E10 onward and 
mature into tissue macrophages via a monocytic intermediate 
(14, 17). Currently, it is not yet resolved why these differences 
in microglia and macrophage ontogenies exist.
Although human microglia ontogeny is not yet studied in 
such detail, immunostaining of the human encephalon indicates 
the presence of IBA1 positive microglia at gestational week 5.5, 
that enter the brain via the ventricles. Microglia proliferate and 
develop toward their typical ramified morphology from that time 
point onward (18). However, the ontogeny of human microglia 
remains to be defined in detail.
Microglia Development Occurs in Four 
Consecutive Stages
A recent study combining transcriptome with epigenome 
analysis identified genes and chromatin modulators that regu late 
different stages of microglia development in mice (19). Micro-
glial gene expression clusters are identified that are specific for 
four sequential developmental phases: YS (E10–12.5), early 
microglia (E10.5–14), pre-microglia [E14—postnatal day 9 
(P9)], and adult (P28 onward). Early, pre- and adult microglia 
are marked by genes related to cell cycle and proliferation (Dab2, 
Mcm5, and Lyz2), synapse pruning (Crybb1, Csf1, and Cxcr2), 
and immune surveillance (Mafb, Cd14, and Mef2a), respectively. 
These developmental stage-specific gene ontology (GO) terms 
(unifying terms annotating a global function to genes) match 
with typical microglia functions, including the involvement in 
neuronal network refinement (synapse pruning) (20, 21) and 
maintenance of adult brain homeostasis (22). Extensive parallel 
single-cell sequencing of microglia identified a high degree of 
homogeneity of microglia populations at specific developmental 
stages. Concordantly, the expression level of developmental 
stage-specific genes correlate to the accessibility of correspond-
ing enhancers identified by dimethylation of lysine 4 on histone 3 
(H3K4me2)-enriched regions distal from the transcription start 
sites of a gene. Whereas YS and embryonic microglia cluster 
more closely together at the transcriptional level, embryonic 
and pre-microglia cluster more closely together at the epigenetic 
level. These results indicate that the microenvironment is driving 
gene expression through modulation of the epigenetic landscape 
into a permissive state for the expression of gene patterns 
belonging to specific developmental phases. This suggestion is 
corroborated by the fact that environmental perturbations, such 
as in germ free (GF) mice and maternal immune activation, led 
to abnormal microgliosis. Mice that are subjected to maternal 
immune activation display a shift from the pre-microglia stage 
toward a more advanced developmental stage, due to a decreased 
expression level of inflammatory and defense related genes. 
It is hypothesized that the disruption of microglia development 
disturbs physiological microglial functions (19).
In addition, specific potential TF binding motifs are identified 
in promotor regions of genes specifically expressed at different 
microglial developmental phases. Clearly, the previously identi-
fied TFs Pu.1 and Irf8 are essential for microglia development 
(15) and are highly upregulated throughout microglia develop-
ment (19). These results corroborate the finding that Pu.1 is 
essential for the gene regulation of several functions including 
myeloid cell differentiation, chemotaxis, and phagocytosis 
(23–25). In line with the findings of Irf8 in the study of Kierdorf 
and coworkers (15), Irf8 is also important in myeloid cell line-
age differentiation and survival during early hematopoiesis in 
zebrafish (26).
The TF Mafb is enriched in adult microglia and the identifi-
cation of immune and viral GO terms, enriched in the pre- and 
adult microglia signature of Mafb-deficient microglia, suggests 
that Mafb is crucial for the regulation of brain homeostasis.
In a similar approach, consistent findings according to micro-
glial developmental stages and stage-specific functions were 
recently identified (27). Interestingly, it was shown that micro-
glia progenitors in the YS and at E10.5 already express a part 
of the homeostatic microglial signature genes (see The Homeo-
static Microglial Gene Signature in Mice and Men), which 
then expand with increasing developmental stage. Based on 
genes expressed at all developmental stages, a murine microglia 
deve lopment signature containing 568 genes was identified and 
compared to gene expression data of FACS-purified microglia 
from human fetuses ranging from 14 to 24 weeks of estimated 
gestational age. This analysis identified 387 overlapping genes, 
involved in functions as immune response and phagocytosis. 
In addition, it was shown that microglia derived from E16.5 
BOx 1 | Environmental influence on the microglial homeostatic gene 
signature.
Evidence is accumulating that genes belonging to the homeostatic microglial 
gene signature are downregulated during neurological diseases. It was shown 
that microglia uniformly downregulate their homeostatic signature genes, such 
as Sall1, Pu.1, Tmem119, Cx3cr1, and P2ry12/13 and upregulate risk genes 
for AD, such as Apoe and Trem2, in mouse models for aging, AD (5XFAD 
and APP-PS1), and amyotrophic lateral sclerosis (ALS) (SOD1) (34–36). 
Interestingly, homeostatic microglial signature genes seem to be differentially 
expressed at different disease stadia in EAE, a mouse model for multiple 
sclerosis (MS). A downregulation of homeostatic microglial signature genes 
is observed in acute and chronic EAE, whereas during the recovery phase 
of EAE, gene levels are restored to those of homeostatic microglia (34, 37). 
Concordantly, a loss of homeostatic microglial signature genes is identified in 
human MS brain tissue (38). Furthermore, homeostatic microglial signature 
genes seem to be at least partially downregulated during aging (33, 39, 40) 
and are differentially expressed in male and female murine microglia (27).
In addition, it was shown that microglia upregulate CD45 expression under 
different disease conditions (8, 41). Furthermore, monocytes downregulate 
Ly6C and Ccr2 during their differentiation into macrophages after infiltrating 
brain tissue (6, 8), resulting in issues regarding the distinction of microglia and 
peripheral monocyte/macrophages in disease conditions.
Concordantly, the use of specific markers to identify microglia under 
specific disease conditions is still controversial.
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mice are developmentally corresponding to microglia derived 
from mid-trimester human fetuses (14–24 weeks of pregnancy). 
Although these human microglia already express genes belong-
ing to the homeostatic microglial gene signature, it should be of 
note that human fetal microglia do not (yet) seem to be sexually 
dimorphic (see Microglial Sexual Dimorphism) (27).
Of importance, it seems that deviations in the microglial deve-
lopmental transcriptome are linked to the development of neu-
rological diseases, such as autism and Alzheimer’s disease (AD) 
in adulthood (28).
In conclusion, microglial development occurs in a complex 
and fine-tuned sequence of processes regulated by environmental 
signals and is associated with specific gene expression programs.
The Homeostatic Microglial Gene 
Signature in Mice and Men
Over the last years, the transcriptome of homeostatic murine 
microglia was identified (2, 3, 29–33). Under homeostatic condi-
tions, this transcriptome contains genes specifically expressed by 
microglia in comparison to other CNS cells and myeloid cells, 
hereafter referred to as homeostatic microglial signature genes. 
These genes are now widely used by other researchers to identify 
and study microglia, also under disease conditions (see Box 1).
The Homeostatic Gene Signature of Murine Microglia
The first gene expression profile of murine microglia was obtained 
in 2012 in a microarray study (32). Based on these expression 
data, that included a common macrophage signature, several 
gene clusters were identified. However, distinct gene expression 
signatures among four different macrophage populations were 
identified. 64 genes, including SiglecH and Cx3cr1 were shown 
to be more abundantly expressed in microglia when compared 
to other investigated macrophage types. Chiu et al. identified 29 
genes that are highly specific for microglia, including Olfml3, 
Tmem119, and SiglecH (31).
Direct RNA sequencing revealed the microglial sensome, 
consisting of 100 cell surface receptors and proteins specific for 
the sensing of microenvironmental factors, including pattern rec-
ognition-, chemokine-, Fc-, purinergic-, cytokine-, extracellular 
matrix-, and cell–cell interaction receptors (33). Approximately 
half of these genes seem to be regulated by Tyrobp (Dap12), a 
protein tyrosine kinase binding protein and ligand for Trem2, 
both belonging to the homeostatic microglial signature genes 
(33). The Trem2–Dap12 signaling pathway seems to be involved 
in (1) the suppression of toll-like receptor (TLR)-induced inflam-
mation, (2) mediating phagocytosis, and (3) reduction of cell 
death and enhancement of myeloid cell proliferation (42). 
Analogous to other studies, Hickman and coworkers identi-
fied several genes that are shared by microglia and other tissue 
macrophages, but also macrophage subtype-specific expression 
of gene sets. The top 25% uniquely expressed genes in microglia 
contain many of the sensome-including genes (33).
In 2014, two studies were published that extensively inves-
tigated microglia and other tissue-resident macrophages at tran-
scriptome level (2, 3). These studies also address the epigenetic 
differences between different macrophage subsets, observing a 
positive correlation with the transcriptome. When comparing 
large peritoneal macrophages (LPM), small peritoneal mac-
rophages (SPM) and microglia at the transcriptional level, both 
macrophages and microglia are depended on Pu.1. However, the 
co-enrichment of different motifs was revealed, LPM and SPM 
are thus shown to be depended on retinoic acid (RA) receptors 
(RAR α/β) whereas motifs as SMAD, consistent with the TGFβ 
signaling in the brain is shown to be unique for microglia (2). 
Analysis of seven different tissue-resident macrophage popula-
tions identified 3.348 differentially expressed genes. K-means 
clustering of these genes led to the discovery that the microglial 
cluster (consisting of 641 genes that are higher expressed in 
microglia) is different from other tissue macrophages, where 
Sall1 is found to be most highly expressed in microglia (3).
A Tgf-β-dependent homeostatic microglial gene signature 
consisting of 152 unique microglial genes, P2ry12, Tmem119, 
Fcrls, and three microRNAs (miRNAs) is identified by compar-
ing the microglial transcription profile to that of other CNS 
cells and monocytes. The validity of these genes being uniquely 
expressed in microglia is confirmed by mass spectrometry, since 
many of these genes are also detected in the enriched fraction of 
microglial proteins. It is shown that Tgf-β is a crucial factor for 
the establishment of the microglial homeostatic gene signature, 
since mice that endogenously lack Tgf-β in CNS tissue show a 
remarkable reduction in microglial numbers and the remaining 
microglia show significantly reduced expression of these homeo-
static microglial signature genes (30).
A transcriptome profile of isolated microglia that closely 
approximates their in vivo status was published by Bennett and 
coworkers, using a relatively non-invasive method to purify 
microglia (29). Inflammation-associated genes (Il1b, Nfkb2, and 
Tnf) are significantly lower expressed in this dataset compared to 
others (2, 31, 32), indicating that in vitro procedures influence the 
homeostatic microglial gene signature (see The Transcriptome 
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of In  Vitro and Ex Vivo Microglia Is Different). Tmem119 was 
studied in detail and was identified to be a specific and, at least at 
protein level, robust microglial marker in mice and human, also 
under inflammatory/disease conditions. In addition, potential 
novel microglial functions associated with vascular development 
(Pdgfb), oligodendrocyte development (Pdgfa), and synapse 
formation (Sparc) are identified and microglial involvement in 
different neurological diseases (Comt, Hprt, and Trem2) are con-
firmed by the enrichment of the indicated genes in microglia (29).
The common denominator of at least these seven studies is 
the identification of the homeostatic microglial signature genes, 
including Sall1, Hexb, Fcrls, Gpr43, Cx3cr1, Tmem119, Trem2, 
P2ry12, Mertk, Pros1, and SiglecH, that are uniquely/higher 
expressed in microglia and not or only at low levels in other brain 
cells or myeloid cell types, including tissue-resident macrophage 
subsets and monocytes.
The Homeostatic Gene Signature of Human Microglia
In parallel to the identification of homeostatic microglial signa-
ture genes in mice, two studies identified homeostatic gene sig-
natures of human microglia. Gosselin and coworkers investigated 
the transcriptomes of microglia purified from healthy-appearing 
brain tissue obtained during neurosurgery of 19 young patients 
(0–17 years) with epilepsy, tumors, or acute stroke. The top 30 
highly expressed genes in that dataset are related to functions 
like microglial ramification and motility (P2RY12 and CX3CR1), 
synaptic remodeling (C3 and C1QA-C), and immune response 
(HLA-DRA and HLA-B). The comparison of microglia-specific 
and whole cortex gene expression profiles identified 881 homeo-
static human microglial signature genes, including CX3CR1, 
P2RY12, and several complement factors as C3, C1QA, C1QB, 
and C1QC. In addition, these human microglial homeostatic 
signature genes significantly overlap with transcriptomic data-
sets related to different neurological diseases, including AD and 
Parkinson’s disease (PD), in which many of the human homeo-
static microglial signature genes are differentially expressed, 
indicating an important role of microglia in the pathophysiology 
of these diseases (43).
Another study identified the homeostatic human microglial 
gene signature from a population of 39 adult (34–102 years) post-
mortem donors in The Netherlands and Brazil. This homeostatic 
microglial gene signature is characterized by 1,297 genes that 
are significantly differentially expressed in purified microglia 
when compared to whole parietal cortex cell lysates. GO analy-
sis indicated that these genes are related to the innate immune 
system, including functions as pathogen and self-recognition, 
inflammasome, cell adhesion and motility (C3XCR1), immune 
signaling and modulation (P2RY12, Q1QA-C, and HLA-DR). 
In addition, risk genes for neurodegenerative diseases, such 
as APOE and TREM2 are enriched in purified adult human 
microglia (39). In addition, the two TFs PU.1 (SPI.1) and IRF8, 
which are also crucial during murine microglia ontogeny and 
development (19) are highly expressed in both datasets (39, 43).
Thus, together these two studies identified the homeostatic 
human microglial gene signature, that shares many genes with 
the murine homeostatic gene signature, but also seem to possess 
human-specific properties.
The homeostatic microglial gene signature is conserved across 
species (39, 43). Comparison of the two homeostatic human 
microglial gene signatures to several homeostatic murine micro-
glial gene signatures reveals an overlap of more than 50%, 
depending on the specific datasets that were compared (39, 43). 
The genes APOC1, MPZL1, SORL1, CD58, ERAP2, GNLY, and 
S100A12, most closely related to the innate immune system, are 
specifically found to be expressed in human microglia and not, or 
only to a very low extent in murine microglia. Concordant with 
the high overlap between murine and human transcriptomes 
are the identified similar epigenetic landscapes, i.e., identified 
microglial-specific regulatory regions, in murine and human 
microglia (43). Concluding, research of recent years has identified 
the homeostatic murine and human microglial gene signatures, 
which enables better identification and investigation of microglia 
in murine and human tissue.
Microglial Sexual Dimorphism
Sex-specific transcriptomic signatures are found when compar-
ing adult male and female mice. A higher gene expression level of 
inflammatory response genes, such as Ccl2, Tnf, Irf1, Cxcl10, and 
Il1b is found in female mice, indicating a more immune-activated 
state of female microglia. In addition, homeostatic microglial 
signature genes are differentially expressed in male and female 
mouse microglia. Interestingly, it is demonstrated that environ-
mental alterations during embryogenesis, like the absence of the 
maternal microbiome (GF mice), has different effects on male and 
female microglial transcriptomes at the identified developmental 
stages (see Microglia Development occurs in Four Consecutive 
Stages). Whereas the transcriptome of microglia from GF 
offspring does not seem to be overtly altered at E14.5 when 
compared to control microglia (under specific pathogen-free 
conditions), it is affected at E18.5 especially in males and in adults 
especially in females, characterized by 1,216 and 433 differentially 
expressed genes, respectively. From those 1,216 differentially 
expressed genes in GF E18.5 males, the majority is downregulated 
and involved in functions such as translation, endocytosis, and 
metabolism. Regarding the 433 differentially expressed genes 
in GF adult female microglia, approximately half of these genes 
are downregulated and involved in the inflammatory response, 
whereas the upregulated genes are associated with the regulation 
of transcription. In addition to transcriptomic changes, the pat-
tern of microglial colonization into the neocortex also occurs in 
a sex-dependent manner in offspring from GF dams. Whereas 
male offspring of GF dams show an increased microglial density 
prenatally (E18.5), female offspring of GF dams show an increased 
microglial density postnatally (P20) (27).
Concordant with the findings by Thion and coworkers a devel-
opmentally more mature state, marked by upregulation of genes 
involved in immune processes, is identified in female microglia 
compared to male microglia at P60. This result is based on the 
microglial developmental index (MDI) that is calculated by the 
ratio of the average expression of globally upregulated genes 
divided by the average expression of globally downregulated 
genes in a developmental time course from E18 to P90 in male 
and female mice (28). Upon lipopolysaccharide (LPS) treatment, 
the MDI of male microglia increases, indicating maturation of 
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male microglia in response to LPS. These sex-dependent baseline 
and LPS-induced changes in the transcriptome are accompanied 
by sex-specific microglial morphologies in the adult hippocam-
pus of mice. When compared to the morphology of baseline 
female microglia, baseline male microglial morphology seems to 
be more complex. It is marked morphologically by an increased 
process volume and area and an increased number of branches 
and intersections, albeit female and male differences are only 
statistically significant for the parameter process volume. Upon 
LPS stimulation, baseline morphological characteristics of male 
microglia get significantly reduced, whereas those of female 
microglia do not change much (28).
Concluding, murine microglia seem to respond to environ-
mental insults in a sex-dependent manner, which was not yet 
manifested in human microglia (27).
Microglia Possess Brain Region-Specific 
Transcription Profiles
Insight in regional heterogeneity of microglial phenotypes can 
provide necessary information on regional specific microglial 
functions. RNA sequencing of bulk samples containing large 
numbers of microglia from the whole brain might mask specific 
regional heterogeneity. Whereas microglia are important for 
general functions including scanning the microenvironment, 
phagocytosis, and neuronal support (22), specific, additional 
regional microglial functions could be envisioned.
Several mouse brain regions were compared, exploring the 
hypothesis that the microenvironment could shape microglial 
functions (40). Regional transcriptional heterogeneity is observed 
when microglia from the mouse cerebral cortex, hippocampus, 
cerebellum, and striatum are compared. Three transcripto-
mic clusters are identified, specific for cerebral cortex/striatum, 
hippocampus, and cerebellum. Annotation of associated bio-
logical processes revealed that the hippocampal microglial gene 
cluster is involved in energy production and regulation, whereas 
the cerebellar and cortical clusters are associated with genes 
involved in immune response and regulation. Concordantly, TF 
binding motif analysis found TFs regulating the expression of 
bioenergetic genes and immune and inflammatory genes to be 
over-represented in the hippocampal- and the cerebellar cluster, 
respectively. Interestingly, there seems to be a difference in the 
immune-activation state of microglia belonging to the cortical 
and the cerebellar cluster. Cortical microglia show an increa-
sed expression of genes coding for inhibitory immunoreceptors, 
including Trem2 and SiglecH, whereas cerebellar microglia show 
an upregulation of genes coding for activating immunorecep-
tors, indicating a more immune-activated microglial phenotype, 
different from the LPS or IL-43-induced microglial phenotypes. 
Notably, approximately one-third of the microglial sensome 
genes (belonging to the homeostatic microglial gene signature) 
are differentially expressed in microglia derived from different 
brain regions. Concluding, although microglia from different 
brain regions share the expression of specific genes, they also 
express region-specific gene sets indicating region-specific micro-
glial functions (40).
De Biase and coworkers reported different microglial 
phenotypes when comparing regions in the basal ganglia. 
The transcriptome of ventral tegmental area (VTA) microglia 
appears to be most distinct when compared to microglia in the 
nucleus accumbens and substantia nigra pars compacta (SNc). 
Differentially expressed genes in microglia of the VTA are 
involved in metabolic processes such as mitochondrial function, 
glycolysis, gluconeogenesis, and oxidative phosphorylation. 
Microglia in the VTA and SNc show limited surveillance and 
contribution in homeostasis, based on observations made in cell 
density, branching, and lysosome content. Based on the overlap-
ping microglial genes in the different regions, classical micro-
glial cell functions are preserved among the different regions. 
However, microglia in different regions also exhibit regional 
adaptation (44), a finding consistent with that of Grabert and 
coworkers.
In another study, microglia were compared with non- 
parenchymal CNS macrophages in the subdural meninges, peri-
vascular spaces, and the choroid plexus on single-cell transcrip-
tome level. Gene expression profiles of microglia and the three 
investigated CNS interface macrophage populations display high 
similarity in contrast to peripheral monocytes. When compared 
to the monocytic transcriptome, microglia and non-parenchymal 
macro phages share 443 differentially expressed genes, such as 
abundant expression of the myeloid markers Cx3cr1, Csfr1, and 
Aif (Iba1). The high overlap of tran scriptomes between these brain-
associated macrophages might be based on their similar ontogeny 
and kinetics, since perivascular and meningeal macrophages, 
ana logous to microglia, also arise during primitive hematopoiesis 
in the YS and are long-lived cells that do not get replenished by 
peripheral monocytes. Besides this commonly expressed gene 
set, microglia and non-parenchymal macrophages also express 
unique separate gene sets. Microglia show differential expression 
of 2,328 unique genes that are unaltered in expression in non-
parenchymal macrophages after comparison to the monocytic 
transcriptome. As an example, P2ry12 and Mrc1 are enriched 
in microglia and perivascular macrophages, respectively, and 
thus are used to distinguish these brain-associated macrophage 
populations (9).
Although not studied such extensively, it seems that human 
microglia also show brain region-specific gene expression 
profiles (45).
Concluding, the CNS is populated by different macrophage 
cell types, and even microglia in the parenchyma can be subdi-
vided into different phenotypes based on their gene expression 
profiles, which might be associated with specific functions.
The Lifetime of Microglia
Microglia, as well as other tissue-resident macrophages (46, 47), 
are stable, self-renewing cell populations over the entire lifespan 
of an animal. The self-renewing capacity of microglia has been 
shown in an experiment where microglia were ablated using 
the Cx3Cr1CreER:iDTR system. Within 5 days the 20% remaining 
microglia completely repopulated the CNS (48). This process 
was independent of infiltration of peripheral monocytes but 
was dependent on microglial interleukin-1 signaling. In a 
similar experiment, where treatment with a macrophage Csf1r 
inhibitor caused ablation of 99% of the resistant microglia, a full 
repopulation of microglia via nestin-positive progenitors within 
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1 week after treatment was observed (49). While it is well accepted 
that, at least under physiological conditions, microglia are not 
replenished by peripheral macrophages, the lifetime of microglia 
is still a matter of debate. Askew and coworkers (50) reported that 
microglia are rather fast proliferating cells with a turnover rate of 
approximately 3 months. By contrast, Füger and coworkers and 
Tay and coworkers propose cortical microglia to be long-lived 
cells with turnover rates between 15 and 41 months, respectively 
(51, 52). Turnover rates of microglia seem to vary between brain 
regions (50–52).
Although studying the lifetime of microglia in humans comes 
along with experimental limitations, estimations of human 
microglia turnover rates was made. It was estimated that the 
human microglia population might renew several 100 times 
within the average human lifetime of 80 years (50). By contrast, 
a relatively slow mean microglial turnover rate of approximately 
28% per year and an average microglial age of 4.2 years is cal-
culated using thymidine analog IdU (5-iodo-2′-deoxyuridine) 
labeling in brains of cancer patients and retrospective atmos-
pheric 14C measurements in the DNA of the same and healthy 
tissue postmortem (53). Clearly, the different microglial turnover 
rates that have been reported may be caused by the use of differ-
ent methodologies and these findings need to be reconciled in 
the future.
Under disease conditions, it has been observed that microglia 
can transiently be replenished by monocyte-derived macrophages 
from the periphery, especially when the blood–brain barrier is 
disrupted (54, 55). In addition, turnover rates of microglia are 
increased under neurodegenerative conditions such as in the 
APP/PS1 mouse model for AD [containing AD risk mutations 
in the genes encoding for the amyloid beta precursor protein 
(App) and presenilin (Psen1/Psen2)] (51), unilateral facial nerve 
axotomy (FNX) in mice (52), and nitroreductase (NTR)-induced 
neurodegeneration in zebrafish larvae (55). Interestingly, during 
the resolution phase of neuroinflammation and -degeneration 
there seems to be a self-regulating mechanism returning micro-
glial numbers in the CNS to physiological conditions. Intravital 
and electron microscopy of zebrafish larvae brains 8 days after 
NTR-induced neurodegeneration has shown that phagocytes 
(microglia and peripheral macrophages) either leave the CNS 
tissue with unknown destination or undergo apoptosis and are 
phagocytosed by viable microglia leading to a physiological 
microglia density in the forebrain numbers resembling those of 
healthy zebrafish (55).
In addition, microglial migration into regions distal to the 
neurodegenerative center as well as microglial apoptosis may 
contribute to the re-establishment of a homeostatic-like 
microglia density in the mouse brain during the resolution 
phase of unilateral FNX-induced neurodegeneration. The 
increased phagocytic activity of microglia identified by confo-
cal microscopy as well as RNA sequencing during later phases 
of neurodegenerative resolution, led to the hypothesis that also 
in mammalian species microglia self-regulate their density by 
phagocytosing excessive microglia that have undergone apop-
tosis. After the resolution of neurodegeneration, a mixture of 
microglia that already existed and newly proliferated microglia 
is preserved (52).
Currently, it is not yet known whether a replicated cell is 
biologically younger or if it inherits (epi)genetic marks from 
the mother cell (51). It was shown that LPS treatment during 
embryonic development results in a dampened immune response 
(LPS tolerance) in the same mice when they are young adults (56), 
indicating that deviations in early microglial development have 
long-lasting effects on the microglial phenotype during aging and 
associated diseases.
THe eFFeCT OF IN VITRO CONDiTiONS 
ON THe HOMeOSTATiC MiCROGLiAL 
GeNe SiGNATURe
Human iPSC (hiPSC)-Derived Microglia-
Like Cells
Restricted numbers of human microglia can be obtained by 
purification from human postmortem and surgically resected 
brain tissue. Unfortunately, limited access to viable human 
brain tissue causes a challenge to study human microglia and 
their respective roles in neurobiological diseases. One possibil-
ity to study human microglia on a relatively large-scale is the 
recent development that microglia-like cells can be generated 
from induced pluripotent stem cells (iPSCs). Thus, various 
studies describe protocols for the differentiation of hiPSCs into 
microglia-like cells. These differentiation protocols recapitulate 
microglial embryonic development and, in some cases, physi-
ologic brain microenvironment in vitro (57–61). The first report, 
published by Muffat and coworkers shows differentiation of 
both human embryonic stem cells and hiPSCs into early YS 
myeloid-like cells and subsequently into mature microglia-like 
cells within 74  days (60). Douvaras and coworkers published 
a protocol that induces myeloid differentiation of hiPSCs into 
CD14+/CX3CR1+ microglial progenitors which mature under 
IL-34 and granulocyte macrophage colony-stimulating fac-
tor (GM-CSF) conditions into microglia in 60 days (58). Two 
other protocols describe the induction of a two-step differen-
tiation process from hiPSCs into hematopoietic progenitor-like 
CD34/CD43/CD45− positive cells into microglia-like cells 
(57, 61). Haenseler and coworkers developed a protocol which 
induces the differentiation of hiPSCs into embryoid bodies 
followed by embryonic macrophage precursors in an M-CSF-, 
IL-3-dependent manner. Co-culturing of these hiPSC-derived 
macrophage precursors and cortical neurons in the pres-
ence of IL-34 and GM-CSF yields microglia-like cells within 
14 days (59).
Human iPSC-derived microglia-like cells show several 
features of microglia in vivo: an amoeboid as well as a ramified 
microglia morphology, expression of microglial markers IBA1, 
CX3CR1, CD11b, CD45, and typical microglial functions such as 
phagocytosis, process motility, secretion of cytokines in response 
to LPS, IL-1β, or INF-γ stimulation, release of intracellular Ca2+ 
in response to adenosine diphosphate (ADP) and cell migration 
toward ADP and into 3D brain organoids (57–61).
To summarize, currently several protocols exist to obtain 
iPSC-derived microglial cells that partially approximate in vivo 
microglia.
7Dubbelaar et al. Microglia Phenotype and Function
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1753
The Transcriptome of In Vitro and Ex Vivo 
Microglia is Different
Although hiPSC-derived microglia display specific in  vivo 
micro glial functions and express a proportion of the homeostatic 
microglial gene signature (57–61), gene expression profiles of 
hiPSC-derived microglia-like cells do not fully match those of 
ex vivo human fetal and adult microglia. Principal component 
analysis (57, 59, 60) and hierarchical clustering (58) of gene 
expression profiles revealed that hiPSC-derived microglia-like 
cells are most similar to cultured primary human microglia 
(57–60), and much less resemble non-cultured ex vivo human fetal 
microglia (61). This finding is confirmed when the transcriptome 
of murine embryonic stem cell-derived microglia is compared 
to the transcriptomes of ex vivo and in vitro murine microglia 
(62). Thus, the in  vitro environment strongly determines their 
gene expression profile, leading to a microglial phenotype differ-
ent from ex vivo microglia.
More specific analysis of in vitro cultured murine and human 
microglia revealed a significant upregulation of inflammatory 
and stress-related genes (30, 43, 63). Cultured microglia show 
repression of homeostatic microglial signature genes (2, 30, 43, 
63, 64) and genes associated with microglial development (43, 63) 
already after 6 h in culture (43). In addition, in vitro conditions 
cause a reduced expression of microglial genes associated with 
different neurodegenerative diseases, e.g., TREM2, in human 
microglia (43). The in  vitro-induced transcriptomic changes 
are mirrored by the observation of a remodeled epigenetic 
landscape of in vitro microglia. Microglia that were cultured for 
7 days lost more than 50% of the super-enhancers identified in 
ex vivo microglia, including the SALL1 super-enhancer (43), 
that regulates microglia identity and function (65). A decrease in 
H3K27Ac levels (associated with active transcription) is observed 
at accessible (ATAC-enriched) regions for microglial TFs, indi-
cating an in  vitro-induced loss of microglial (super-) enhancer 
activity. This finding is corresponding with the downregulation 
of ex vivo microglia-specific genes and TFs (43).
These findings suggest that cultured microglia are less mature 
and have a more inflammatory phenotype than ex vivo human 
microglia. As a consequence, transcriptomic discrepancies bet-
ween ex vivo and in vitro microglia are challenging the validity 
of current in vitro microglia culture systems to study murine and 
human microglia physiology and pathology.
Interestingly, Spaethling and coworkers were able to dis-
tinguish different brain cell types (neurons, oligodendrocytes, 
astrocytes, and microglia) after surgically obtained brain tis-
sue was kept in culture for 3 weeks, with k-means clustering 
of cell-specific markers based on single-cell RNA sequencing 
data. Although the comparison between cultured microglia 
with ex vivo microglia has not been performed, the current 
results suggest that in vitro microglia lose many genes belong-
ing to the homeostatic gene signature, though microglia can 
still be segregated from other brain cells in single-cell sequenc-
ing analysis (66).
Various studies have aimed to reveal crucial microenvi-
ronmental factors in in vitro culturing systems, that drive micro-
glial identity toward a more in vivo-like state (30, 63). Whereas 
the astrocyte-secreted factors Tgf-β2, Csf1, and cholesterol are 
identified as microglial survival factors in vitro (63), Tgf-β sup-
plementation of culturing media only led to partial (2, 30, 43) 
or no (63) re-establishment of an ex vivo-like microglial gene 
expression profile in cultured microglia.
Concluding, the gap in conformity between gene expression 
profiles of ex vivo and in vitro microglia is likely caused by the 
lack of yet unknown CNS microenvironmental factors that 
keep microglia in a homeostatic state in currently used in vitro 
culture systems.
Microglia isolation Procedures Affect 
Their Transcriptome
Next to the in vitro cell culture conditions, it should be of note 
that other in vitro procedures, such as the isolation procedure 
of microglia (tissue dissociation and cell sorting) can affect their 
gene expression profile, leading to the possibility that currently 
used reference ex vivo microglia expression data might not 
completely reflect in vivo microglia. In fact, it was shown that 
microglia inflammatory activation markers (Il1b, Tnf, and Ccl2) 
are already upregulated prior to placing murine microglia into 
culture, indicating that the isolation procedure by itself already 
affects the microglial phenotype (63). In addition, evidence 
indicates that enzymatic dissociation of brain tissue at 37°C 
leads to the upregulation of inflammatory genes in microglia 
when compared to mechanical dissociation at 4°C [(29); Eggen 
et  al., unpublished data] or to the cTag-PAPERCLIP method 
(based on genetically modified animals and does not require 
tissue dissociation) (67).
In order to minimize the introduction of in vitro-induced arti-
facts when working with microglia in culture, the development 
of culture conditions and dissociation procedures that result in 
in vitro microglia that highly resemble microglia in vivo is of great 
importance.
MiCROGLiAL ACTivATiON STATeS FROM 
A TRANSCRiPTOMe POiNT OF view
Functional and Morphological Aspects  
of Microglial Activation
“Microglial activation” is an umbrella term commonly used to 
describe a great variety of functional and morphological res-
ponses of microglia toward different triggers including stress 
(= homeostatic imbalance), inflammation, or chronic neurode-
generative conditions.
While this term implies that microglia are in a dormant 
state under healthy/homeostatic conditions, already more than 
10  years ago, two photon-imaging of the mouse cortex in  vivo 
showed that microglial protrusions are highly motile in order to 
scan their microenvironment for harmful exogenous and endog-
enous danger signals (68, 69). In addition, microglia are highly 
motile under healthy conditions during development. Synaptic 
pruning, the elimination of excessive, non-active neurons formed 
early in development, is realized by complement-dependent 
phagocytic activity of microglia (20, 21).
Microglia in a healthy brain are characterized by a small soma 
from which ramified protrusions are extending a morphology 
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evolutionary conserved in different species (70). Classically, 
microglial activation was associated with an amoeboid-like 
morphology that enables microglia motility and phagocytic func-
tion (22). However, morphological transformation of microglia 
upon a shift in activation state does not seem to be uniform. 
Microglial morphologies range from amoeboid-like under 
inflammatory conditions (71) to hyper-ramification in response 
to stress (72) and accelerated aging (73), with many intermedi-
ate morphologies in between. In addition, different microglia 
morphologies can also be present at a defined condition such as 
stroke (74). Thus, it seems that there is, based on morphology, 
a yet unclear number of microglial activation states and single- 
cell resolution experiments are required to address that issue 
in detail. Since the discovery of microglia a century ago, we are 
aware of the wide range of morphologies microglia can adopt 
(12), though for most conditions direct links between a specific 
morphology and functionality of microglia are still unknown.
A Brief History of Categorizing Concepts 
for Macrophage and Microglial Activation
An early concept that was first postulated for peripheral mac-
rophages is the dichotomous categorization of macrophage 
acti vation states into classical activation (M1) or alternative 
activation (M2), analogous to the Th1 and Th2 nomenclature of 
T-lymphocytes (75). In an attempt to structure the complexity 
of microglial activation, the same M1-M2 classification was 
applied to activation states of microglia. The M1 phenotype is 
characterized by the production of pro-inflammatory cytokines 
(Tnf-α, Il-6, and Il-1β), chemokines, and reactive oxygen species 
leading to an acute immune response. The M2 phenotype is char-
acterized by the production of anti-inflammatory cytokines (Il-4 
and Il-13) and facilitates debris clearance, wound healing, and 
restoration of brain tissue homeostasis (76, 77). It was assumed 
that microglia react to a stimulus with an M1 phenotype to 
address pathology and damage, followed by transition to an M2 
phenotype in order to execute tissue repair (78). More detailed 
understanding led to the acceptance that microglial activation 
states are diverse and that intermediates between M1 and M2 
phenotype exist (76). Further development of this concept in the 
macrophage field suggested to refine the M1-M2 nomenclature 
by adding the triggering stimulus as an abbreviation to the M1 
or M2 classification (77).
Transcriptome studies revisited this concept by disproving 
the existence of the mutual exclusive M1-M2 polarization states. 
M1-M2-associated genes (77) were co-expressed by murine 
monocyte-derived brain macrophages/microglia in the context 
of traumatic brain injury (79) and ALS (31). Moreover, tran-
scriptome-based network analysis of human monocyte-derived 
macrophages exposed to 29 different stimuli in  vitro revealed 
that each stimulus triggered the expression of a distinct tran-
scription profile. These profiles expand far beyond the M1-M2-
associated transcription profiles and under some conditions, 
M1- and M2-markers are solely expressed at baseline level 
(80). This study indicates that the concept of an activation spec-
trum in between the M1-M2 extremes is inadequate.
Recent studies have thus led to the abandonment of this static 
and outdated M1-M2 concept of microglial (81) and macrophage 
activation (82) states and point toward the adaption of a so-called 
“multidimensional concept.” This concept incorporates ontogeny, 
microenvironmental signals, as well as present and past endog-
enous and exogenous stress signals (83). Such a concept would 
be in line with current knowledge gained from (single cell) 
transcriptome and epigenome studies about the great variety of 
microglial activation states specific to different conditions includ-
ing aging and neurodegenerative diseases (84).
The Microglial Transcriptome During 
Aging
Murine Aged Microglia
During aging, microglia undergo several phenotypic changes 
including in morphology and function (85). The microglial 
phenotype in aging was extensively studied in a mouse model 
of accelerated aging that is marked by genotoxic stress due to 
deficiency of the DNA-repair protein Ercc1. Microglia in generic 
Ercc1 mutant mice have a hyper-ramified morphology accom-
panied by increased proliferation rates. Upon LPS stimulation, 
microglia from Ercc1 mutant mice show enhanced expression of 
pro-inflammatory cytokines (Il-1β, Il-6, and Tnf-α), enhanced 
phagocytic activity, and reactive oxygen species production when 
compared to wild-type mice. This exaggerated responsiveness of 
microglia in aged and in Ercc1 deficient, accelerated-aging mice is 
referred to as priming. The primed immune state was confirmed 
by transcriptional profile analysis, identifying an upregulation of 
genes associated with immune-related signaling pathways (73). 
This microglial phenotype was also observed in mice where 
the Ercc1 deficiency was targeted to forebrain neurons. These 
data suggest that genotoxic stress in neurons could induce the 
observed primed state in microglia.
Overall, aging seems to induce a phagocytic and antigen-
presentation gene expression profile when microglial transcrip-
tomes of young and old mice are compared. Microarray analysis 
of pure microglia from young and old mice showed that aged 
microglia obtain a gene expression profile that is characterized 
by upregulation of genes involved in phagocytosis (including 
Clec7a and Axl), antigen processing and antigen presentation, 
interferon and cytokine signaling, as well as lipid homeostasis 
(including Apoe). The increased phagocytic activity in aged/
senescent microglia is confirmed by a functional phagocytosis 
assay. Primed microglia are primarily detected in the white mat-
ter of the aging murine brain (86).
Similarly Orre and coworkers (87), identified 482 genes (e.g., 
Slp1, Apoe, Il1r2, and Ccr6) more abundantly expressed in corti-
cal microglia at least by twofold in aged mice (15–18  months) 
when compared to younger mice (2.5 months). These genes are 
involved in processes such as vesicle release, zinc ion binding, 
positive regulation of cell proliferation, lymphocyte activation, 
and inflammatory response, indicating increased microglia-
neuron signaling and an inflammatory status within the aging 
murine brain (87).
Interestingly, microglia in different regions of the mouse brain 
show divergent sensitivities to aging. Mainly genes involved 
in immune regulatory processes are differentially expressed in 
microglia upon aging. Cerebellar microglia seem to be most 
prone to aging-induced transcriptional differences, as they 
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differentially express more than the double number of genes at 
22 months of age, when compared to cortical, hippocampal, and 
striatal microglia of that age. Most of the differentially expressed 
genes in 22  months old microglia were upregulated genes 
involved in immunoregulatory functions. Age-related transcrip-
tomic changes in cortical and cerebellar microglia occur relatively 
consistent during early (4–12 months) and late (12–22 months) 
aging. Gene expression changes during early aging (4–12 months) 
are most prominent in the striatum and during late aging 
(12–22 months) in the hippocampus. Microglia lose the expres-
sion of homeostatic microglial signature genes such as P2ry12/13, 
Tmem119, and Fcrls, most prominently in the cerebellum and 
to a lesser extent in the hippocampus, cortex, and striatum. 
These findings suggest that in addition to age-induced effects on 
microglia in the white matter, age-associated changes in microglia 
occur in a brain region-specific manner (40, 86).
In contrast to the general notion that microglia obtain a primed 
profile (40, 86, 87) and are neurotoxic during aging and age-related 
diseases (88), Hickman and coworkers identified a neuroprotec-
tive gene expression profile of microglia derived from the entire 
brain in aged mice (24  months) due to upregulation of genes 
involved among others in the Stat3 and Neuregulin-1 pathways. 
Aging affects the microglia sensome: receptors for endogenous 
ligands are downregulated while receptors for microbial ligands 
are upregulated (33).
Human Aged Microglia
An age-related increase in immunoreactivity for inflammatory-
related microglial markers, CD68 and HLA-DR, as well as increased 
binding of a PET tracer for activated microglia ([11C]-(R)-PK11195) 
has been identified in the white matter of human postmortem 
brain tissue (86). Whereas these findings indicate that similar to 
mouse, human microglia adopt a more activated phenotype dur-
ing aging, transcriptomic analysis identified that the overlap in 
genes that change expression during aging in mouse and human 
is very limited. Of note, mouse and human microglia overlap 
extensively with respect to the expression of homeostatic signature 
genes (39).
In the human transcriptomic dataset of Galatro and coworkers 
(39), 572 genes are differentially expressed in relation to the age 
of the donor. 212 genes are increased and 360 genes decreased in 
expression, and many of these genes are related to cytoskeleton, 
motility, and immune response processes. The top 100 most dif-
ferential expressed genes in human microglia during aging are 
associated with actin (dis)assembly, cell surface receptors, and 
genes involved in cell adhesion and axonal guidance. Upregulated 
genes are mainly associated with actin (dis)assembly and motil-
ity, indicating a loss of microglia motility and migration in aged 
human microglia, a factor that might contribute to age-related 
CNS diseases. Genes involved in cell adhesion and axonal guid-
ance and the sensome cell surface receptors are partially upregu-
lated and downregulated (e.g., P2RY12) (39).
The overlap in genes that are differentially expressed during 
aging between humans and mice is very limited (39). Only 14 
upregulated genes overlapped between the human and mouse 
data and are involved in positive regulation of cell-matrix adhe-
sion. Nine genes have a reduced expression during aging in both 
human and mice, identifying genes as ETS1, SEMA7A, MRC2, 
PSTPIP1, and EMP2 (39). Concluding, the response of microglia 
to aging is different in mouse and human.
Although not yet completely understood, microglia seem 
to obtain an age-induced immune-activated phenotype during 
aging, which likely contributes to the pathology of neurodegen-
erative diseases including AD and PD (85, 88–90). In contrast to 
mice, human microglia also adapted their cytoskeleton signaling 
during aging (7).
The Transcriptomic Point of view on 
Activated Microglial Phenotypes in 
Neurodegenerative Diseases
A shared feature among different neurodegenerative disorders 
is microglia-mediated neuroinflammation (91). This type of 
microglial activation is a first line of defense in the CNS, but 
is also described as harmful (91, 92). Microglial activation can 
be observed in different neurodegenerative diseases in which 
microglia obtain specific phenotypes.
Alzheimer’s Disease
Several AD studies reported activated microglia surrounding 
Aβ plaques (34, 35, 93, 94). Plaque-associated microglia in the 
5XFAD AD-mouse model (co-expresses five mutations associated 
with familial AD) contain upregulated sets of genes that overlap 
with the primed microglia transcriptional profile (95), that is 
characterized by enrichment of genes involved in among others 
immune and phagocytic processes, like Apoe, Axl, and Clec7a. 
Key protein regulators of those upregulated genes are Tyrobp 
(Dap12) and CD11c (Itgax). Of note, plaque-associated microglia 
in 5XFAD mice show an upregulation of phagocytosis-associated 
genes. Interestingly, the same phagocytic markers, APOE, AXL, 
TREM2, and HLA-DR are shown to be higher expressed in 
microglia surrounding dense-core plaques of early onset AD 
human postmortem tissue, when compared to late onset AD 
(LOAD) (94). In contrast to the finding that the expression of 
TYROBP is unaltered between plaque and non-plaque-associated 
microglia of LOAD postmortem brain tissue (94), TYROBP is 
identified as a key regulator of microglial-associated genes, based 
on the construction of a molecular network from autopsied whole 
brain samples of 1647 LOAD and non-demented subjects (96). 
Kamphuis and coworkers identified two distinct subsets (CD11c− 
and CD11c+) in the CD11b+ microglia population surrounding 
Aβ plaques in APP/PS1 mice. Transcriptional alterations are 
more abundant in the CD11c+ population when compared to 
CD11c− microglia, including an upregulation of Clec7a, Itgam, 
Ctsb, and Cst7 expression. The CD11c+ microglial population is 
enriched for genes involved in a dampened immune response, 
carbohydrate and lipid metabolism, phagocytosis and lysosomal 
degradation, suggesting that the CD11c+ population is active 
in the clearance of amyloid deposition by possibly increased 
phagocytic and lysosomal activity and restriction of the inflam-
matory response (93). By contrast, it was recently observed that 
innate immune activity (inflammasome activity) of microglia 
leads to Aβ accumulation in APP/PS1 mice. Although not dis-
tinguishing between CD11c microglia subsets, it is shown that 
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microglia secrete inflammasome-associated adaptor proteins, 
called apoptosis-associated speck-like proteins containing a 
CARD (caspase recruitment domain; ASC). ASC proteins can 
go through a cascade of modifications that lead to the assembly 
of large extracellular paranuclear ASC protein complexes, called 
ASC specks. These ASC specks are prone to bind Aβ deposits 
throughout brain tissue of AD patients and APP/PS1 transgenic 
mice. They are identified as the key contributors to several AD 
characteristics, such as the formation of plaques and spatial 
memory loss (97).
Concluding, the contradiction between the hypothesized 
function of CD11c+ microglia (clearance of Aβ plaques) and 
the proven function of CD11b+ microglia (augmentation of Aβ 
plaques), might be explained by the fact that CD11c+ microglia 
only constitute approximately 23% of the total activated CD11b 
microglial population (93), whereby its potential neuroprotective 
function might be overruled by the neurotoxic function of the 
remaining microglia.
Interestingly, single-cell analysis of hippocampal microglia 
from CK-p25 mice, a mouse model of severe AD-like neuro-
degeneration, identified a stepwise microglial gene expression 
trajectory in response to neurodegeneration. One week after CK- 
p25 induction, microglia possess an early-response state, which 
is hallmarked by an upregulation of genes involved in cell cycle, 
DNA replication, and repair. Increased incorporation of the 
thymidine analog EdU (5-Ethynyl-2′-deoxyuridine) and micro-
glial density in CK-p25 mice 1 week after induction confirmed 
microglial proliferation in response to early neurodegeneration. 
Two and six weeks after disease induction, late-response micro-
glia, show upregulation of immune response-related genes, such 
as Ccl3/4, Apoe, Axl, and H2D1. This microglial phenotype can 
be divided into two immune-activated subtypes that are marked 
by co-regulated genes induced by interferon type I (antiviral 
and interferon response genes) and II (MHC-II complex-related 
genes), respectively. Whether these microglial phenotypes have 
neuroprotective or neurotoxic functions remains unknown (98).
Multiple Sclerosis
Multiple sclerosis lesions have been categorized into (1) pre-
active lesions, characterized by microglia activation in the 
absence of overt demyelination, (2) active lesions with massive 
infiltration of microglia and monocyte-derived macrophages, 
(3) mixed active/inactive lesions that consists of a hypocellular 
center and a foamy macrophage/microglia-enriched rim with 
partial demyelination, and (4) inactive lesions that are absent of 
cells and completely demyelinated. MS lesions are surrounded 
by normal appearing white matter, where microglial activation 
may occur as well (99). It is very difficult to interpret the dis-
tinct roles of microglia and monocyte-derived macrophages in 
MS pathology, since both macrophage populations are present 
in MS lesions (6). This mixed cell population of microglia and 
monocyte-derived macrophages has been investigated on tran-
scriptomic level in human MS tissue (38, 100). Attempts have 
been made to decipher the role of microglia and peripheral 
monocytes in an experimental autoimmune encephalomyelitis 
(EAE, myelin-oligodendrocyte-glycoprotein peptide (MOG)-
induced) mouse model for MS (37, 101). Yamasaki and coworkers 
distinguished microglia from monocyte-derived macrophages 
by the use of genetically modified mice that express fluorescent 
proteins (green or red fluorescent proteins) expressed under the 
control of a microglial (Cx3cr1) or monocytic (Ccr2) promoter. 
The study showed that microglia and monocyte-derived mac-
rophages from the same tissue have different phenotypes in EAE. 
At the onset and peak of disease, microglia upregulated genes that 
are involved in the complement system (e.g., C1qa, C3, and C4), 
chemotaxis (e.g., Ccl2/4), cell migration, and acute inflammation 
(e.g., Il1β and Tnf) and downregulated genes that are involved 
in cell metabolism. By contrast, the gene expression profile of 
monocyte-derived macrophages is characterized by phagocy-
tosis-, autophagy-, and cell clearance-related genes. Along with 
the finding that solely monocyte-derived macrophages form 
contacts at nodes of Ranvier, it was suggested that monocyte-
derived macrophages initiate demyelination at EAE onset, 
whereas microglia seem to be responsible for the attraction of 
monocyte-derived macrophages to the CNS and to clear debris 
(37). Similar results have been reported in a study that used CD44 
protein expression levels to distinguish microglia (CD44low) from 
monocyte-derived macrophages (CD44high) in EAE. RNA expres-
sion analysis of microglia and monocyte-derived macrophages 
from EAE mouse brain tissue reveal that macrophages display 
a more pronounced immune activation phenotype at the peak 
of EAE, characterized by common activation markers such as 
MHCII, CD40, and CD86. In comparison with monocyte-derived 
macrophages, microglia upregulate genes involved in uptake of 
apoptotic cells, the complement signaling, and chemotaxis at the 
peak of EAE (101).
In conclusion, these above studies suggest that monocyte-
derived macrophages and microglia have different roles during 
the disease progression of EAE. Monocyte-derived macrophages 
seem to be the mediators of demyelination, whereas microglia 
are primarily responsible for the induction of peripheral 
infiltration to the CNS and clearance of apoptotic neurons in 
EAE. Whether these different macrophage phenotypes exist in 
human MS pathology as well needs to be addressed in future 
experiments.
Parkinson’s Disease
Microglial activation is initiated by several components, 
whereas one of the most frequently altered genes in familial 
PD is α-synuclein (91). Overexpression of a-synuclein led to 
the activation of BV2 cells, a microglial cell line, measured 
by an increase in cytokine production (102). Since in  vitro 
cultured microglia do not resemble in vivo microglia (see The 
Transcriptome of In Vitro and Ex Vivo Microglia Is Different), 
the microglial phenotype associated with PD in vivo yet remains 
to be elucidated.
Whole tissue lysate small RNA sequence analysis of post-
mortem prefrontal cortex of PD patients (demented and non- 
demented) and control subjects, identified a set of 29 PD-related 
miRNAs (103). Interestingly two Pu.1 related micro RNA’s 
(miR146a and miR-155) (36, 104) are upregulated in PD sub-
jects, suggesting that microglia might be activated in human 
PD. Single-cell laser captured microglia of human postmortem 
PD brain tissue were used to identify microglial gene expression 
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in PD (45). Overall, the most differentially expressed genes 
in microglia derived from PD subjects compared to control 
subjects are involved in functions such as aldosterone synthesis 
and secretion, positive regulation of protein complex assembly, 
focal adhesion assembly, tonic smooth muscle contraction, and 
positive regulation of reactive oxygen species biosynthetic pro-
cesses. 313 genes are differently expressed in microglia located 
in the substantia nigra when compared to the CA1 hippocampal 
region of PD patients. These genes are involved in the behavior, 
regulation of transport, and synaptic transmission processes. 
The above findings indicate regional differences in microglial 
functioning in PD (45). Concluding, overall the expression 
pattern of genes in PD points toward microglial activation. 
Unfortunately, the small number of PD microglia transcript 
studies limit the current conclusion.
Amyotrophic Lateral Sclerosis
An activated microglial phenotype was reported in the transgenic 
SOD1-G93A mouse model for ALS, that contains mutations in 
the human superoxide dismutase 1 gene. The microglial phe-
notype is identified as a neurodegeneration-specific phenotype 
and differs from LPS-activated microglia as well as from M1- or 
M2 macrophages (31). It was shown that microglia in SOD1-
G93A mice simultaneously upregulate neurotoxic and neuro-
protective factors as well as pro-inflammatory-related genes 
(e.g., Tnfα and Il-1β). In addition, an upregulation of genes that 
have been associated with AD, including Trem2, Tyrobp, and 
Apoe associated with AD are found in microglia from SOD1-
G93A mice. Furthermore, Apoe is also upregulated in both 
SOD1-G93A mice and ALS subjects (sporadic and familial) 
(36). At least for in vitro conditions, Apoe seems to play a role in 
forcing the “surveilling” microglia toward an immune-activated 
(M1-like) phenotype (36). In addition, a downregulation of the 
homeostatic microglial signature genes (including P2ry12 and 
CD39), transcriptional factors (including Egr1, Atf3, Fos, and 
Mafb), developmental genes (such as Tgfb1, Tgfbr1, and Csf1r), 
and genes related to phagocytic ability and cell migration was 
described in SOD1-G93A mice (36). This indicates a suppres-
sion of several homeostatic microglial functions. Interestingly, 
the microRNA-155 (miR-155) is identified to be upregulated 
in microglia of SOD1-G93A mice as well as in spinal cord tissue 
of ALS subjects (36).
Genetic ablation of miR-155 in SOD1 mice causes a delay of the 
disease onset, an extend of the animal survival rates, and reversed 
the expression of SOD1-related upregulation of inflammatory 
genes and downregulation of homeostatic genes in microglia. In 
conclusion, miR-155 seems to be an important factor in driving 
the phenotypic switch from homeostatic to SOD1-specific acti-
vation microglia. Therefore, miR-155 might be a potential new 
therapeutic target in ALS (36).
MiCROGLiAL CORe GeNe SiGNATUReS 
ASSOCiATeD wiTH DiFFeReNT 
DiSeASeS
Next to the identification of disease-specific microglial tran-
scriptomes, in the past years several studies have addressed a 
core profile of microglial genes that are dysregulated in multiple 
neurodegenerative diseases (34, 35, 95).
Massively parallel single-cell RNA-sequencing of CD45+ 
immune cells revealed among others the presence of three novel 
microglial transcriptional subpopulations in 5XFAD mice that 
are not present in wild-type animals. Two of them are character-
ized by the expression of genes involved in lipid metabolism and 
phagocytosis and are specifically located near Aβ plaques in the 
cortex of AD mice, called disease-associated microglia (DAM). 
DAMs seem to undergo a cascade of subsequent changes in 
gene expression profiles alongside the progression of the disease. 
The first step includes an increased expression of Tyrobp, Apoe, 
and B2m and reduced expression of microglial homeostatic 
signature genes (Cx3cr1 and P2ry12). There seems to be a 
Trem2-dependency from the second step onward together with 
the upregulation of genes involved in lipid metabolism and 
phagocytic activity, such as Lpl, Cst7, Axl, and Clec7a. DAMs 
have also been identified in postmortem human AD tissue and 
in a mouse model for ALS (mSOD1 mice). Moreover, appear-
ance of DAMs was observed when CD11b+ immune cells are 
compared between brains of young (7  weeks old) and aged 
(20 months old) mice. These findings suggest that DAMs (35) 
might have a general neuroprotective function involved in the 
clearance of accumulating proteins observed in aged and age-
related neurodegenerative diseases brain tissue (105).
In contrast to the hypothesized neuroprotective function 
of DAMs, investigation of bulk microglial transcriptomes in 
different disease models led to the identification of a microglial 
neurodegenerative/-toxic (MGnD) phenotype that is dependent 
on the Trem2-Apoe pathway. These MGnD are found adjacent 
to Aβ plaques in APP/PS1 mice and human AD postmortem 
brain tissue and in SOD1, EAE, and aged (17  months) mice. 
Two major transcriptional changes are observed in MGnD: (1) 
the downregulation of microglial homeostatic genes [including 
Tgfb(r), Hexb, P2ry12, and Cx3cr1] and TFs (including Mef2a, 
Mafb, and Sall1) and (2) the upregulation of inflammatory genes 
(including Axl, Itgax, Clec7a, and Apoe), leading to a switch 
from a homeostatic to a neurodegenerative/-toxic microglial 
phenotype. This switch seems to be induced by the phagocytosis 
of apoptotic neurons and is dependent on Trem2-Apoe signal-
ing and accompanied by a suppression of the Tgfβ pathway. 
Depletion of Trem2 in APP/PS1 and SOD1 mice suppresses the 
expression of inflammatory genes, including Apoe, restores the 
homeostatic microglia gene signature and functions, and also 
alleviates disease-specific characterizations such as reduced 
Aβ plaques in APP/PS1 mice and reduced expression of miR-155 
in SOD1 mice. Interestingly, the microglial homeostatic pheno-
type seems to be preserved in human AD patients who carry a 
mutation in the TREM2 gene when compared to AD patients 
with wild-type TREM2 (34).
Compared to the results of Krasemann and Keren-Shaul, a 
similar set of genes, including Apoe, Axl, Itgax, Lgals3, Clec7a, 
MHC-II, and Cxcr4, was identified as a commonly upregulated 
network of genes in different mouse models of aging [physiolo-
gical aging and accelerated aging (24 months; Ercc1 deficient)] 
and murine disease models (APP/PS1 and SOD1) when compared 
to acute immune activation with LPS. This network is classified 
TABLe 1 | Gene overlap of different microglial core profiles associated with 
multiple diseases.
Compared studies Overlapping genes
Keren-Shaul et al. (35) and 
Krasemann et al. (34)
BIN1, CCR5, CD34, CKB, CTSD, CX3CR1, 
ENTPD1, EPB4.1L2, F11R, FSCN1, GPR34, 
GPR56, LGMN, LTC4S, OLFML3, P2RY12, 
P2RY13, PMEPA1, RHOB, SERPINE2, SIGLECH, 
SLCO2B1, SPARC, SYNGR1, TMEM119, and 
TREM2
Holtman et al. (95) and 
Keren-Shaul et al. (35)
ANK, APLP2, B2M, CD52, CD68, CD9, CLEC7A, 
CSF1, CST7, CTSB, CTSZ, EEF1B2, GRN, 
GUSB, H2-K1, HIF1A, ITGAX, LGALS3BP,  
NPC2, PLD3, PSAT1, and TYROBP
Holtman et al. (95) and 
Krasemann et al. (34)
CXCL16, CCL5, and GAS7
Holtman et al. (95), 
Krasemann et al. (34), and 
Keren-Shaul et al. (35)
APOE, AXL, and IGF1
FiGURe 1 | Overlapping gene signatures of microglial core profiles 
associated with multiple diseases identified in three independent studies. 
Using the “primed” module by Holtman and coworkers (95), the gene profile 
of disease-associated microglia identified by Keren-Shaul and coworkers (35) 
and the gene profile of the microglial neurodegenerative phenotype identified 
by Krasemann and coworkers (34), three genes were identified to be shared 
among the three microglia datasets associated with multiple diseases.
12
Dubbelaar et al. Microglia Phenotype and Function
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1753
as the “microglia priming” network and is associated with func-
tions involved in AD signaling, antigen presentation, lysosome 
and phagosome pathway. In addition, it was found that microglial 
homeostatic genes are suppressed in this “primed” network. The 
“primed” gene expression network related to microglial activa-
tion is contrasting with an “acute” activation network, specific for 
acute microglial inflammatory response to LPS that is marked by 
an upregulation of genes involved in ribosome, TLR signaling, 
and NOD-like receptor signaling (95).
Summarizing, different studies identified a microglial gene 
signature associated with multiple diseases that is marked by the 
downregulation of microglial homeostatic signature genes and 
the upregulation of genes associated with inflammation, phago-
cytosis, and lipid metabolism, whereby the two genes Apoe and 
Trem2 seemed to be crucial players. Whereas the upregulation 
of phagocytic genes might imply neuroprotective functions of 
microglia (35, 93), recent studies show that microglia also seem 
to have a neurodegenerative/-toxic function in multiple neurode-
generative diseases (34, 97).
By comparing these aging- and neurodegeneration-associated 
microglial core gene signatures (34, 35, 95), an overlap between 
the different gene signatures (modules) is determined and 
visualized in Figure 1. A summary of the overlapping aging- and 
neurodegeneration-associated genes is depicted in the Venn 
diagram and are is listed in Table 1 where the annotation of gene 
functions is done with stringDB (106). There are three genes iden-
tified that are shared among these three datasets: APOE, AXL, and 
IGF1, identifying a very limited overlap of microglial-associated 
disease genes between three studies that have investigated similar 
age-related disease mouse models.
DiSCUSSiON
The diversity of microglial phenotypes can be metaphorically 
imagined as the manifold compositions of colorful crystals seen 
in a kaleidoscope, whereby a change in (micro)environment 
is functionally equivalent to a rotation of the kaleidoscope. 
Technological developments in next-generation sequencing 
provide the possibility to reveal cell-type specific transcriptomes 
at single-cell resolution. Over the last 5 years, different studies 
have concordantly established the microglial gene signatures 
in mice and humans under homeostatic conditions (2, 3, 
29–33, 39, 43). In addition, microglia-specific gene signatures 
in different neurological disease contexts were investigated. 
Summarizing, it was shown that the expression of many of the 
homeostatic microglial signature genes are repressed during 
aging and age-related CNS diseases. It is expected that more 
transcriptomic studies will follow, especially in regard to neu-
ropsychiatric disease, from which transcriptome datasets are 
currently very sparse.
Identification of microglial genes that are highly expressed and 
shared between different neurodegenerative diseases and aging 
might result in the identification of regulators that can alter affected 
pathways in multiple diseases. Thus far, three core signatures of 
microglia associated with multiple diseases have been identified 
(34, 35, 95). Although, microglial transcriptomes under similar 
conditions (aging and models for AD, MS, and ALS) have been 
evaluated in these three studies, only a limited overlap of genes is 
identified (see Figure 1), indicating that other factors might have 
influenced the transcriptional outcome. Figure 2 depicts exam-
ples of parameters, such as development, aging, sex, diseases, 
and experimental procedures, that were shown to influence 
microglial transcriptomes and might have led to the different 
results of the above-mentioned studies. In order to identify a 
“pure” microglial core signature related to multiple CNS dis-
eases, the only deviating factor between the compared datasets 
should be “disease/disease model.” Obviously, this cri terion is 
difficult to meet in a laboratory setup and is mere impossible 
in datasets derived from the human population. Conversely, 
the question arises whether the overlap of disease-associated 
microglial datasets, that are influenced by other factors, indeed 
identifies a universal regulator that is most important for all dif-
ferent investigated disease phenotypes. In view of the fact that 
FiGURe 2 | The kaleidoscope of microglial phenotypes: complexity of 
determining a microglial core profile associated with multiple diseases. This 
figure depicts examples of factors that impinge on the microglia epigenome 
and transcriptome. Seven factors are depicted that have been shown to 
influence the microglial transcriptome: brain region, ontogeny, disease, age, 
sex, experimental procedures, and species. The influence of these factors on 
the transcriptome converges in the center of the gray rim. This rim represents 
the imprint of these factors on the epigenome, which yet remains to be 
revealed.
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research is often pursued in order to identify drug targets for 
human diseases, it is questionable if identification of a multiple 
disease-associated core signature of microglia will lead to a 
universal drug target for multiple diseases or whether disease-
specific regulators might be more suitable as drug targets.
Current studies have delineated the influences of several 
environmental events (see Figure 2) on the microglial transcrip-
tome. These findings indicated that microglia “imprint” different 
events on their (epi)genome and that imprints that occur early in 
life can possibly influence microglial phenotype over the entire 
lifespan of an animal. Although the precise microglial turnover 
rate is not yet completely clarified, microglia seem to be quite 
long-lived cells further supporting a potential role of epigenetics 
in regulating microglial function. Investigation of the microglial 
epigenetic landscape under homeostasis has already provided 
valuable insight in the (micro)environmental-induced dynamics 
of chromatin modifications and how these affect gene expres-
sion (2, 3, 43). Although currently unknown, investigation of 
the microglial epigenetic landscape in context of CNS diseases 
would reveal the link between the CNS-disease related micro-
environment and the corresponding transcriptome and would 
definitely contribute to a better understanding of the role of 
microglia in the pathophysiology of CNS diseases.
One of the recent developments in sequencing technology 
is the ability to decipher transcriptomes and epigenomes at 
the resolution of a single cell (107, 108). The identification of 
single-cell transcriptomes and epigenomes will greatly facilitate 
the characterization of distinct microglial phenotypes under 
particular conditions, ranging from (ab)normal development to 
neurodegenerative disease, and allow for a detailed and sophisti-
cated functional classification of microglial phenotypes.
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